ResistancePlus® GC (CE-IVD)
simultaneously detects the bacterium Neisseria gonorrhoeae (GC) and the gyrA S91 (wild type) or gyrA S91F (mutant) markers that are associated with susceptibility or resistance to the fluoroquinolone antibiotic Ciprofloxacin. ResistancePlus® GC based on the Class-leading PlexPCR® technology utilising two proprietary technologies: PlexZyme® and PlexPrime®. This technology enables high performance and reliable multiplex qPCR compared to other probe-based methods.
| Targets | Single well, N. gonorrhoeae (Opa), N. gonorrhoeae (PorA), Ciprofloxacin resistance, Ciprofloxacin susceptibility, Internal control |
| Validated Sample Types | Urine, swabs (anal, rectal, cervical, endocervical, vaginal, urethral, pharyngeal, and eye), pre-extracted samples |
| Storage & Stability | Expiry dates are stated on the labels. It is recommended that freeze/thaw cycles be limited to less than 15. Store protected from light at – 20°C. |
| Validated RT-PCR Systems | LightCycler® 480 Instrument II (LC480 II, Roche), Applied Biosystems® 7500 Fast (7500 Fast), Applied Biosystems® 7500 Fast Dx (7500 Fast Dx), Bio-Rad CFX96™ IVD (CFX96 IVD), Bio-Rad CFX96™ CFX96 Touch™ (CFX96 Touch) |
| Package Size | 25 reactions/box |
Sexually Transmitted Infections
Why use ?
Antibiotic resistance in gonorrhoea infections is a global concern. There are limited effective treatment options and novel antibiotics are not readily available. Smarter and more directed use of antibiotics can be achieved through Resistance Guided Therapy.
• Global surveillance data indicate 50-70% of gonorrhoea infections remain susceptible to ciprofloxacin.
• Guidelines for gonorrhoea management call to preserve ceftriaxone and recommend use of ciprofloxacin when susceptibility information is available.
• Azithromycin resistance is rising, compromising dual-therapy options.
Tested on hundreds of clinical samples, demonstrates excellent sensitivity and specificity.